Trademark: 79252849
Word
FREELINE
Status
Registered
Status Code
700
Status Date
Tuesday, February 4, 2020
Serial Number
79252849
Registration Number
5974485
Registration Date
Tuesday, February 4, 2020
Mark Type
5000
Filing Date
Monday, November 19, 2018
Published for Opposition
Tuesday, November 19, 2019

Trademark Owner History
Freeline Therapeutics Limited - Original Registrant

Classifications
40 Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
5 Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
The mark consists of the word "FREELINE" in stylised text.
FREE LINE
Color is not claimed as a feature of the mark.

Trademark Events
Feb 4, 2023
Change Of Name/Address Rec'd From Ib
Aug 6, 2022
New Representative At Ib Received
Jun 5, 2020
Final Decision Transaction Processed By Ib
May 18, 2020
Final Disposition Notice Sent To Ib
May 18, 2020
Final Disposition Processed
May 4, 2020
Final Disposition Notice Created, To Be Sent To Ib
Feb 4, 2020
Registered-Principal Register
Nov 19, 2019
Official Gazette Publication Confirmation E-Mailed
Nov 19, 2019
Published For Opposition
Nov 15, 2019
Notification Processed By Ib
Oct 30, 2019
Notification Of Possible Opposition Sent To Ib
Oct 30, 2019
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Oct 30, 2019
Notification Of Notice Of Publication E-Mailed
Oct 17, 2019
Assigned To Lie
Oct 10, 2019
Approved For Pub - Principal Register
Sep 20, 2019
Teas/Email Correspondence Entered
Sep 20, 2019
Correspondence Received In Law Office
Sep 20, 2019
Teas Response To Office Action Received
Apr 6, 2019
Refusal Processed By Ib
Mar 21, 2019
Non-Final Action Mailed - Refusal Sent To Ib
Mar 21, 2019
Refusal Processed By Mpu
Mar 12, 2019
Non-Final Action (Ib Refusal) Prepared For Review
Mar 11, 2019
Non-Final Action Written
Mar 8, 2019
Application Filing Receipt Mailed
Mar 4, 2019
Assigned To Examiner
Mar 4, 2019
New Application Office Supplied Data Entered
Mar 1, 2019
Limitation From Original Application Entered
Feb 28, 2019
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24